tacrolimus apotex tacrolimus 5 mg capsule blister pack
pharmacor pty ltd - tacrolimus monohydrate, quantity: 5.1 mg (equivalent: tacrolimus, qty 5 mg) - capsule - excipient ingredients: dichloromethane; lactose; magnesium stearate; croscarmellose sodium; ethanol absolute; hypromellose; titanium dioxide; purified water; iron oxide red; gelatin; sodium lauryl sulfate - tacrolimus is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.
pharmacor tacrolimus tacrolimus 5 mg capsule blister pack
pharmacor pty ltd - tacrolimus monohydrate, quantity: 5.1 mg (equivalent: tacrolimus, qty 5 mg) - capsule - excipient ingredients: lactose; dichloromethane; croscarmellose sodium; hypromellose; ethanol absolute; magnesium stearate; titanium dioxide; purified water; iron oxide red; gelatin; sodium lauryl sulfate - tacrolimus is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.
pharmacor tacrolimus tacrolimus 1 mg capsule blister pack
pharmacor pty ltd - tacrolimus monohydrate, quantity: 1.02 mg (equivalent: tacrolimus, qty 1 mg) - capsule - excipient ingredients: hypromellose; magnesium stearate; dichloromethane; lactose; ethanol absolute; croscarmellose sodium; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - tacrolimus is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.
prograf tacrolimus 0.5mg capsule blister pack
astellas pharma australia pty ltd - tacrolimus, quantity: 0.5 mg - capsule, hard - excipient ingredients: lactose monohydrate; croscarmellose sodium; purified water; iron oxide yellow; magnesium stearate; hypromellose; titanium dioxide; gelatin; hyprolose; butan-1-ol; iron oxide red; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf is indicated for use as an adjunct to liver, kidney, heart or lung allograft transplantation in adults and children.
prograf tacrolimus 5mg capsule blister pack
astellas pharma australia pty ltd - tacrolimus, quantity: 5 mg - capsule, hard - excipient ingredients: lactose monohydrate; hypromellose; iron oxide red; gelatin; magnesium stearate; titanium dioxide; croscarmellose sodium; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf is indicated for use as an adjunct to liver, kidney, heart or lung allograft transplantation in adults and children.
prograf tacrolimus 1mg capsule blister pack
astellas pharma australia pty ltd - tacrolimus, quantity: 1 mg - capsule, hard - excipient ingredients: titanium dioxide; croscarmellose sodium; hypromellose; magnesium stearate; lactose monohydrate; gelatin; purified water; hyprolose; butan-1-ol; iron oxide red; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf is indicated for use as an adjunct to liver, kidney, heart or lung allograft transplantation in adults and children.
advagraf xl tacrolimus 3 mg prolonged-release capsules blister pack
astellas pharma australia pty ltd - tacrolimus, quantity: 3 mg - capsule - excipient ingredients: hypromellose; ethylcellulose; lactose monohydrate; magnesium stearate; titanium dioxide; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.
lenalide lenalidomide 25 mg capsules blister pack
juno pharmaceuticals pty ltd - lenalidomide, quantity: 25 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.
lenalide lenalidomide 15 mg capsules blister pack
juno pharmaceuticals pty ltd - lenalidomide, quantity: 15 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.
lenalide lenalidomide 20 mg capsules blister pack
juno pharmaceuticals pty ltd - lenalidomide, quantity: 20 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified water; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.